People News: AstraZeneca and Pfizer

AstraZeneca hired Pfizer's Martin Mackay to lead research and development, and Pfizer named Wyeth R&D chief Mikael Dolsten to lead its R&D efforts. Dolsten, who led Wyeth R&D from May 2008 through the close of the company's acquisition by Pfizer, becomes president, Pfizer Worldwide R&D. Mackay, who was president, PharmaTherapeutics R&D at Pfizer, becomes president of R&D at AstraZeneca, with responsibility for delivering new drugs and biologics. Replacing him at Pfizer is SVP and head of worldwide research for PharmaTherapeutics R&D Rod MacKenzie, who will add responsibility for Asia R&D strategy to his current duties leading small molecule research.  

You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.